Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 16, 2020

Sanofi and Translate Bio find positive preclinical Covid-19 vaccine results

Sanofi’s vaccines global business unit Sanofi Pasteur and Translate Bio have reported preclinical trial results that showed mRNA-based vaccine candidate, MRT5500 induced a favourable immune response against SARS-CoV-2.

Sanofi’s vaccines global business unit Sanofi Pasteur and Translate Bio have reported preclinical trial results that showed mRNA-based vaccine candidate, MRT5500 induced a favourable immune response against SARS-CoV-2.

These results support progressing the vaccine candidate into clinical development, with a Phase I / II trial expected to commence in the fourth quarter of this year.

Sanofi Pasteur and Translate Bio are developing MRT5500 as part of a partnership deal.

Four dose levels of the vaccine candidate were evaluated at 0.2µg, 1µg, 5µg and 10µg in mice using a two-dose schedule administered three weeks apart.

In non-human primates (NHPs), three dose levels of 15µg, 45µg and 135µg MRT5500 were analysed with a similar two-dose approach.

Data showed that the vaccine candidate induced dose-dependent levels of binding antibodies and neutralising antibodies specific to SARS-CoV-2 spike protein significantly higher than those observed in patients with Covid-19.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

Moreover, MRT5500-immunised mice and NHPs demonstrated a Th1-biased T-cell response against SARS-CoV-2.

Translate Bio CEO Ronald Renaud said: “The preclinical results we report in this paper demonstrate the ability of MRT5500 to elicit a favourable immune response in both mice and non-human primates.

“Importantly, these results provide additional support for using our mRNA platform to potentially expedite the development of alternative approaches to traditional vaccines.”

In 2018, the companies signed a collaboration and exclusive license agreement to develop mRNA vaccines for up to five infectious disease pathogens.

Initially, the deal expanded in March to include the development of a novel mRNA vaccine for Covid-19.

Sanofi Pasteur executive vice-president and global head Thomas Triomphe said: “Today’s presentation of these positive results is another development milestone for providing a safe and effective potential vaccine against SARS-CoV2 and shows how promising this technology is.”

In September, Sanofi and GlaxoSmithKline (GSK) initiated a Phase I / II trial to evaluate their adjuvanted recombinant protein-based vaccine candidate against Covid-19.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU